Does the media favor TMDX or SGP?

In the previous week, Spyglass Pharma had 5 more articles in the media than TransMedics Group. MarketBeat recorded 7 mentions for Spyglass Pharma and 2 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 1.62 beat Spyglass Pharma's score of -0.02 indicating that TransMedics Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Spyglass Pharma 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ESTA or SGP?

In the previous week, Spyglass Pharma had 4 more articles in the media than Establishment Labs. MarketBeat recorded 7 mentions for Spyglass Pharma and 3 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.16 beat Spyglass Pharma's score of -0.02 indicating that Establishment Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyglass Pharma 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LMAT or SGP?

In the previous week, LeMaitre Vascular had 1 more articles in the media than Spyglass Pharma. MarketBeat recorded 8 mentions for LeMaitre Vascular and 7 mentions for Spyglass Pharma. LeMaitre Vascular's average media sentiment score of 0.75 beat Spyglass Pharma's score of -0.02 indicating that LeMaitre Vascular is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyglass Pharma 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AXGN or SGP?

In the previous week, Spyglass Pharma had 1 more articles in the media than AxoGen. MarketBeat recorded 7 mentions for Spyglass Pharma and 6 mentions for AxoGen. AxoGen's average media sentiment score of 0.59 beat Spyglass Pharma's score of -0.02 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Spyglass Pharma 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SGP or BFLY?

In the previous week, Spyglass Pharma had 5 more articles in the media than Butterfly Network. MarketBeat recorded 7 mentions for Spyglass Pharma and 2 mentions for Butterfly Network. Butterfly Network's average media sentiment score of 0.00 beat Spyglass Pharma's score of -0.02 indicating that Butterfly Network is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyglass Pharma 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Butterfly Network 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Spyglass Pharma (SGP) Competitors

$20.00 +0.24 (+1.19%)

As of 12:07 PM Eastern

Compare

SGP vs. TMDX, ESTA, LMAT, AXGN, and BFLY

Should you buy Spyglass Pharma stock or one of its competitors? MarketBeat compares Spyglass Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spyglass Pharma include TransMedics Group (TMDX), Establishment Labs (ESTA), LeMaitre Vascular (LMAT), AxoGen (AXGN), and Butterfly Network (BFLY). These companies are all part of the "medical equipment" industry.

How does Spyglass Pharma compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and Spyglass Pharma (NASDAQ:SGP) are both medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

TransMedics Group has a net margin of 27.04% compared to Spyglass Pharma's net margin of 0.00%. TransMedics Group's return on equity of 22.38% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	27.04%	22.38%	8.46%
Spyglass Pharma	N/A	N/A	N/A

In the previous week, Spyglass Pharma had 5 more articles in the media than TransMedics Group. MarketBeat recorded 7 mentions for Spyglass Pharma and 2 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 1.62 beat Spyglass Pharma's score of -0.02 indicating that TransMedics Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Spyglass Pharma	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

TransMedics Group presently has a consensus target price of $134.50, suggesting a potential upside of 84.28%. Spyglass Pharma has a consensus target price of $45.00, suggesting a potential upside of 124.94%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Spyglass Pharma is more favorable than TransMedics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

TransMedics Group has higher revenue and earnings than Spyglass Pharma. Spyglass Pharma is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	4.17	$190.29M	$4.40	16.59
Spyglass Pharma	N/A	N/A	N/A	-$6.41	N/A

99.7% of TransMedics Group shares are held by institutional investors. 6.9% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

TransMedics Group beats Spyglass Pharma on 10 of the 13 factors compared between the two stocks.

How does Spyglass Pharma compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and Spyglass Pharma (NASDAQ:SGP) are both medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Establishment Labs presently has a consensus price target of $90.43, suggesting a potential downside of 3.30%. Spyglass Pharma has a consensus price target of $45.00, suggesting a potential upside of 124.94%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Spyglass Pharma is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Spyglass Pharma has a net margin of 0.00% compared to Establishment Labs' net margin of -19.05%. Spyglass Pharma's return on equity of 0.00% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
Spyglass Pharma	N/A	N/A	N/A

In the previous week, Spyglass Pharma had 4 more articles in the media than Establishment Labs. MarketBeat recorded 7 mentions for Spyglass Pharma and 3 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.16 beat Spyglass Pharma's score of -0.02 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyglass Pharma	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

72.9% of Establishment Labs shares are held by institutional investors. 10.0% of Establishment Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Spyglass Pharma has lower revenue, but higher earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	13.04	-$51.06M	-$1.49	N/A
Spyglass Pharma	N/A	N/A	N/A	-$6.41	N/A

Summary

Spyglass Pharma beats Establishment Labs on 7 of the 13 factors compared between the two stocks.

How does Spyglass Pharma compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and Spyglass Pharma (NASDAQ:SGP) are both medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

84.6% of LeMaitre Vascular shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

LeMaitre Vascular presently has a consensus target price of $112.60, indicating a potential upside of 10.83%. Spyglass Pharma has a consensus target price of $45.00, indicating a potential upside of 124.94%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Spyglass Pharma is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, LeMaitre Vascular had 1 more articles in the media than Spyglass Pharma. MarketBeat recorded 8 mentions for LeMaitre Vascular and 7 mentions for Spyglass Pharma. LeMaitre Vascular's average media sentiment score of 0.75 beat Spyglass Pharma's score of -0.02 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyglass Pharma	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

LeMaitre Vascular has a net margin of 24.35% compared to Spyglass Pharma's net margin of 0.00%. LeMaitre Vascular's return on equity of 15.36% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
Spyglass Pharma	N/A	N/A	N/A

LeMaitre Vascular has higher revenue and earnings than Spyglass Pharma. Spyglass Pharma is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	9.30	$57.73M	$2.71	37.49
Spyglass Pharma	N/A	N/A	N/A	-$6.41	N/A

Summary

LeMaitre Vascular beats Spyglass Pharma on 10 of the 13 factors compared between the two stocks.

How does Spyglass Pharma compare to AxoGen?

AxoGen (NASDAQ:AXGN) and Spyglass Pharma (NASDAQ:SGP) are both medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

AxoGen currently has a consensus price target of $46.50, indicating a potential upside of 18.16%. Spyglass Pharma has a consensus price target of $45.00, indicating a potential upside of 124.94%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Spyglass Pharma is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Spyglass Pharma has lower revenue, but higher earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	9.29	-$15.70M	-$0.64	N/A
Spyglass Pharma	N/A	N/A	N/A	-$6.41	N/A

In the previous week, Spyglass Pharma had 1 more articles in the media than AxoGen. MarketBeat recorded 7 mentions for Spyglass Pharma and 6 mentions for AxoGen. AxoGen's average media sentiment score of 0.59 beat Spyglass Pharma's score of -0.02 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyglass Pharma	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spyglass Pharma has a net margin of 0.00% compared to AxoGen's net margin of -13.21%. Spyglass Pharma's return on equity of 0.00% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
Spyglass Pharma	N/A	N/A	N/A

80.3% of AxoGen shares are held by institutional investors. 2.4% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Spyglass Pharma beats AxoGen on 7 of the 13 factors compared between the two stocks.

How does Spyglass Pharma compare to Butterfly Network?

Spyglass Pharma (NASDAQ:SGP) and Butterfly Network (NYSE:BFLY) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Spyglass Pharma currently has a consensus target price of $45.00, indicating a potential upside of 124.94%. Butterfly Network has a consensus target price of $5.56, indicating a potential downside of 14.23%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Spyglass Pharma is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Butterfly Network	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Spyglass Pharma has higher earnings, but lower revenue than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	-$6.41	N/A
Butterfly Network	$97.61M	16.92	-$77.06M	-$0.30	N/A

In the previous week, Spyglass Pharma had 5 more articles in the media than Butterfly Network. MarketBeat recorded 7 mentions for Spyglass Pharma and 2 mentions for Butterfly Network. Butterfly Network's average media sentiment score of 0.00 beat Spyglass Pharma's score of -0.02 indicating that Butterfly Network is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Butterfly Network	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

37.9% of Butterfly Network shares are owned by institutional investors. 22.0% of Butterfly Network shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Spyglass Pharma has a net margin of 0.00% compared to Butterfly Network's net margin of -73.63%. Spyglass Pharma's return on equity of 0.00% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
Butterfly Network	-73.63%	-34.41%	-23.91%

Summary

Spyglass Pharma beats Butterfly Network on 8 of the 13 factors compared between the two stocks.

Get Spyglass Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGP vs. The Competition

Export

Metric	Spyglass Pharma	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$668.83M	$3.14B	$4.38B	$12.38B
Dividend Yield	N/A	N/A	37.90%	9.36%
P/E Ratio	-3.12	21.54	23.67	24.04
Price / Sales	N/A	250.41	134.95	112.77
Price / Cash	N/A	9.02	30.17	48.09
Price / Book	N/A	5.69	12.18	6.17
Net Income	N/A	$23.43M	$120.21M	$331.75M
7 Day Performance	0.53%	-6.58%	-1.40%	-1.52%
1 Month Performance	6.98%	-8.49%	-1.78%	-1.24%
1 Year Performance	N/A	1.69%	11.15%	17.64%

Spyglass Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGP Spyglass Pharma	1.7444 of 5 stars	$20.01 +1.2%	$45.00 +124.9%	N/A	$668.83M	N/A	N/A	65	News Coverage
TMDX TransMedics Group	4.5413 of 5 stars	$74.37 -1.8%	$134.50 +80.8%	-32.7%	$2.57B	$605.49M	16.90	210
ESTA Establishment Labs	1.4705 of 5 stars	$85.65 -2.6%	$89.71 +4.8%	+122.7%	$2.52B	$211.08M	N/A	1,004	Positive News
LMAT LeMaitre Vascular	3.9813 of 5 stars	$98.70 -1.6%	$112.60 +14.1%	+27.4%	$2.26B	$249.60M	36.42	490
AXGN AxoGen	2.8608 of 5 stars	$39.28 -0.5%	$46.50 +18.4%	+253.3%	$2.09B	$225.21M	N/A	450	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGP) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spyglass Pharma (SGP) Competitors

SGP vs. TMDX, ESTA, LMAT, AXGN, and BFLY

How does Spyglass Pharma compare to TransMedics Group?

Summary

How does Spyglass Pharma compare to Establishment Labs?

Summary

How does Spyglass Pharma compare to LeMaitre Vascular?

Summary

How does Spyglass Pharma compare to AxoGen?

Summary

How does Spyglass Pharma compare to Butterfly Network?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGP vs. The Competition

Spyglass Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spyglass Pharma (SGP) Competitors

SGP vs. TMDX, ESTA, LMAT, AXGN, and BFLY

How does Spyglass Pharma compare to TransMedics Group?

Is TMDX or SGP more profitable?

Does the media favor TMDX or SGP?

Do analysts recommend TMDX or SGP?

Which has stronger valuation and earnings, TMDX or SGP?

Do institutionals & insiders have more ownership in TMDX or SGP?

Summary

How does Spyglass Pharma compare to Establishment Labs?

Do analysts recommend ESTA or SGP?

Is ESTA or SGP more profitable?

Does the media refer more to ESTA or SGP?

Do institutionals and insiders have more ownership in ESTA or SGP?

Which has stronger valuation & earnings, ESTA or SGP?

Summary

How does Spyglass Pharma compare to LeMaitre Vascular?

Do insiders & institutionals hold more shares of LMAT or SGP?

Do analysts prefer LMAT or SGP?

Does the media refer more to LMAT or SGP?

Is LMAT or SGP more profitable?

Which has stronger valuation and earnings, LMAT or SGP?

Summary

How does Spyglass Pharma compare to AxoGen?

Do analysts prefer AXGN or SGP?

Which has stronger earnings & valuation, AXGN or SGP?

Does the media prefer AXGN or SGP?

Is AXGN or SGP more profitable?

Do institutionals and insiders believe in AXGN or SGP?

Summary

How does Spyglass Pharma compare to Butterfly Network?

Do analysts recommend SGP or BFLY?

Which has stronger earnings and valuation, SGP or BFLY?

Does the media refer more to SGP or BFLY?

Do institutionals and insiders believe in SGP or BFLY?

Is SGP or BFLY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGP vs. The Competition

Spyglass Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools